GlassScriptPhysician profile
Gary Browning Berner
NPI 1659639664
$386.31
in general payments reported to CMS, 2019-2025
16 companies · $40.02 in 2025
The $40.02 reported for 2025 was less than what a typical Adolescent Medicine (Internal Medicine) provider received nationally (typical 2025 total: $165).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.61 · 2021: $13.94 · 2022: $42.33 · 2023: $214 · 2024: $60.60 · 2025: $40.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $314.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $70.50 | 2022-2024 | Farxiga, Flumist Quadrivalent |
| Baxter Healthcare | $62.56 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Supernus Pharmaceuticals, INC. | $40.02 | 2025 | |
| Corium, LLC | $25.14 | 2023 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.48 | 2023 | |
| Novo Nordisk INC | $19.69 | 2024 | Rybelsus, Ozempic |
| Xeris Pharmaceuticals, INC. | $17.61 | 2022 | |
| Dexcom, INC. | $16.97 | 2023 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $16.53 | 2023 | Austedo Xr |
| Neurocrine Biosciences, INC. | $15.61 | 2024 | Ingrezza |
| Phadia US INC. | $15.61 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.85 | 2023 | Abilify Asimtufii, Rexulti |
| Boston Scientific Corporation | $13.94 | 2021 | |
| Lilly USA, LLC | $13.45 | 2023 | Mounjaro |
| Horizon Therapeutics Plc | $11.80 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $11.55 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Berner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.